Device to control circadian-effective light in Alzheimer's disease environments

在阿尔茨海默病环境中控制昼夜节律有效光的装置

• 批准号: 10448533
• 负责人: Erik Page
• 金额: $ 1.8万
• 依托单位: BLUE IRIS LABS, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10448533
• 关键词: Affect; Agitation; Algorithms; Alzheimer' s Disease; Alzheimer' s disease related dementia; Back; Behavior; Biological Clocks; Building Codes; Characteristics; Clinical Trials; Cognition; Data; Database Management Systems; Development; Device or Instrument Development; Devices; Dose; Effectiveness; Elderly; Environment; Feeds; Health; Hour; Human; Human Biology; Image; Institutes; Internet; Intervention; Knowledge; Laboratories; Light; Lighting; Machine Learning; Measurement; Measures; Monitor; Moods; Nursing Homes; Optics; Patients; Pattern; Performance; Periodicity; Phase; Phototherapy; Planet Earth; Population; Process; Reporting; Research; Research Personnel; Retina; Rotation; Running; Sleep; Stimulus; System; Technology; Testing; Time; Vision; Visual; Visual system structure; Wakefulness; Wireless Technology; Work; active control; alertness; appropriate dose; awake; base; biological systems; circadian; circadian pacemaker; cloud based; commercialization; design; dosage; effectiveness testing; experience; falls; field study; health data; improved; interest; meter; next generation; novel; prototype; residence; response; success; therapy design

Project Summary This proposed project will develop and field-test a device that accurately monitors and controls the circadian stimulus (CS) for Alzheimer disease (AD) and Alzheimer-disease-related dementia (ADRD) patients in nursing homes. Human biology has evolved to have two distinct optical systems: the visual system, by which we see and process images, and the circadian system, which regulates our biological clock and associated biological systems. These two systems have significantly different spectral and temporal responses to optical input. Specifically, circadian stimulation peaks at 460 nm and responds after several minutes of optical activation, while the visual system peaks at 555 nm and responds nearly instantaneously to inputs. All lighting systems are designed and installed in buildings with consideration only given to the photopic (visual) system and all light meters used to characterize lighting buildings are calibrated to measure photopic light, not CS. While a broad and growing body of research has documented the impacts of the circadian system on human health, including regulating sleep and improving cognition in AD/ADRD patients, research on the CS experienced by AD/ADRD patients is extremely limited. Researchers at the Lighting Research Center at Rensselaer Polytechnic Institute developed the Daysimeter, a calibrated light meter that measures circadian light and circadian stimulus. In Phase I of this project, researchers modified an existing workstation-based lighting control system they previously developed for the visual system to include Daysimeter technology, allowing this control system to record CS measurements. The accuracy of these CS measurements was confirmed in the laboratory and field-testing of 20 of devices is currently ongoing in AD/ADRD nursing homes. In this Phase II application, researchers propose adding control features to this device so that lighting can be controlled to optimize CS dosages in AD/ADRD patient environments. Machine learning-based lighting control algorithms will be driven by continuous light level and spectrum measurements as well as periodic (e.g., daily) patient health data. Data from these devices would be wirelessly transmitted to researchers via an Internet gateway and associated cloud-based data management systems. These data would be of immediate value for gaining a better understanding of AD/ADRD patients' CS exposure and could ultimately result in new lighting systems and/or building codes that consider both our visual and circadian systems. Following the development phase, 30 CS-enabled lighting control systems will be field tested over a 22-week test period. Researchers aim to commercialize this CS-enabled lighting control system shortly after the completion of this field test and the Phase II project specifically targeting AD/ADRD nursing home applications.

项目摘要 这个拟议的项目将开发和现场测试一种设备，准确地监测和控制昼夜节律 阿尔茨海默病（AD）和阿尔茨海默病相关痴呆（ADRD）患者的刺激（CS）， 养老院人类生物学已经进化出两个不同的光学系统：视觉系统， 我们看到和处理图像，昼夜节律系统，调节我们的生物钟和相关的 生物系统。这两个系统具有显著不同的光谱和时间响应， 输入.具体而言，昼夜节律刺激在460 nm处达到峰值，并在几分钟的光学刺激后响应。 激活，而视觉系统在555 nm处达到峰值，并几乎立即响应输入。所有照明 在建筑物中设计和安装系统时，只考虑明视（视觉）系统 并且用于表征照明建筑物的所有测光表都被校准以测量明视光，而不是CS。 虽然越来越多的研究已经证明了昼夜节律系统对人类的影响， 健康，包括调节AD/ADRD患者的睡眠和改善认知，CS研究 AD/ADRD患者的经验非常有限。照明研究中心的研究人员在 伦斯勒理工学院开发了Daysimeter，一种测量昼夜节律的校准光度计 光和昼夜节律刺激。在该项目的第一阶段，研究人员修改了现有的基于工作站的 照明控制系统，他们以前开发的视觉系统，包括Daysimeter技术， 允许该控制系统记录CS测量值。这些CS测量的准确性为 在AD/ADRD护理中，目前正在对20种器械进行实验室和现场测试 木屋.在第二阶段的应用中，研究人员建议为该设备添加控制功能， 可以控制以优化AD/ADRD患者环境中的CS剂量。基于机器学习的 照明控制算法将由连续的亮度级和光谱测量驱动， 周期性的（例如，每日）患者健康数据。来自这些设备的数据将被无线传输到 研究人员通过互联网网关和相关的基于云的数据管理系统。这些数据将 对于更好地了解AD/ADRD患者的CS暴露具有直接价值， 最终导致新的照明系统和/或建筑规范，考虑到我们的视觉和昼夜节律 系统.在开发阶段结束后，30个CS照明控制系统将在一年内进行现场测试。 22-周测试期。研究人员的目标是在2010年10月10日之后不久将这种支持CS的照明控制系统商业化。 完成该现场测试和专门针对AD/ADRD疗养院的第二阶段项目 应用.